Literature DB >> 29443386

Technical Note: Error metrics for estimating the accuracy of needle/instrument placement during transperineal magnetic resonance/ultrasound-guided prostate interventions.

Ester Bonmati1, Yipeng Hu1, Barbara Villarini1,2, Rachael Rodell1, Paul Martin1, Lianghao Han1,3, Ian Donaldson4, Hashim U Ahmed4,5,6, Caroline M Moore4, Mark Emberton4, Dean C Barratt1.   

Abstract

PURPOSE: Image-guided systems that fuse magnetic resonance imaging (MRI) with three-dimensional (3D) ultrasound (US) images for performing targeted prostate needle biopsy and minimally invasive treatments for prostate cancer are of increasing clinical interest. To date, a wide range of different accuracy estimation procedures and error metrics have been reported, which makes comparing the performance of different systems difficult.
METHODS: A set of nine measures are presented to assess the accuracy of MRI-US image registration, needle positioning, needle guidance, and overall system error, with the aim of providing a methodology for estimating the accuracy of instrument placement using a MR/US-guided transperineal approach.
RESULTS: Using the SmartTarget fusion system, an MRI-US image alignment error was determined to be 2.0 ± 1.0 mm (mean ± SD), and an overall system instrument targeting error of 3.0 ± 1.2 mm. Three needle deployments for each target phantom lesion was found to result in a 100% lesion hit rate and a median predicted cancer core length of 5.2 mm.
CONCLUSIONS: The application of a comprehensive, unbiased validation assessment for MR/US guided systems can provide useful information on system performance for quality assurance and system comparison. Furthermore, such an analysis can be helpful in identifying relationships between these errors, providing insight into the technical behavior of these systems.
© 2018 American Association of Physicists in Medicine.

Entities:  

Keywords:  accuracy validation; focal therapy; image-guided interventions; needle placement; prostate cancer; targeted biopsy

Mesh:

Year:  2018        PMID: 29443386     DOI: 10.1002/mp.12814

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  5 in total

1.  Lumbar nerve root blocks using MRI - the effectiveness and safety of ultrasound/MRI fusion image guidance.

Authors:  David John Wilson; Gina Allen; Stuart Bullock; Jon Denton
Journal:  Br J Radiol       Date:  2022-01-07       Impact factor: 3.629

2.  Magnetic resonance imaging-ultrasound fusion-targeted biopsy combined with systematic 12-core ultrasound-guided biopsy improves the detection of clinically significant prostate cancer: Are we ready to abandon the systematic approach?

Authors:  Christopher Antonio Febres-Aldana; Sarah Alghamdi; Thomas A Weppelmann; Emilio Lastarria; Akshay Bhandari; Yumna Omarzai; Robert J Poppiti
Journal:  Urol Ann       Date:  2020-10-15

3.  Magnetic resonance imaging/transrectal ultrasonography fusion guided seed placement in a phantom: Accuracy between 2-seed versus 1-seed strategies.

Authors:  Qian Li; Yu Duan; Masoud Baikpour; Theodore T Pierce; Colin J McCarthy; Ashraf Thabet; Suk-Tak Chan; Anthony E Samir
Journal:  Eur J Radiol       Date:  2020-06-10       Impact factor: 3.528

4.  Initial phantom studies for an office-based low-field MR system for prostate biopsy.

Authors:  Selin Chiragzada; Eva Hellman; Duncan Michael; Ram Narayanan; Aleksandar Nacev; Dinesh Kumar
Journal:  Int J Comput Assist Radiol Surg       Date:  2021-04-23       Impact factor: 2.924

5.  The SmartTarget Biopsy Trial: A Prospective, Within-person Randomised, Blinded Trial Comparing the Accuracy of Visual-registration and Magnetic Resonance Imaging/Ultrasound Image-fusion Targeted Biopsies for Prostate Cancer Risk Stratification.

Authors:  Sami Hamid; Ian A Donaldson; Yipeng Hu; Rachael Rodell; Barbara Villarini; Ester Bonmati; Pamela Tranter; Shonit Punwani; Harbir S Sidhu; Sarah Willis; Jan van der Meulen; David Hawkes; Neil McCartan; Ingrid Potyka; Norman R Williams; Chris Brew-Graves; Alex Freeman; Caroline M Moore; Dean Barratt; Mark Emberton; Hashim U Ahmed
Journal:  Eur Urol       Date:  2018-12-06       Impact factor: 20.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.